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The extent to which antibiotic-resistant bacteria are excreted by humans who have not been exposed to
antibiotics is not known. Children, who rarely receive fluoroquinolones, provide opportunities to assess the
frequency of fecal excretion by fluoroquinolone-naı¨ve hosts of fluoroquinolone-resistant gram-negative bacilli.
Fresh nondiarrheal stools from children were processed by screening them on agar containing ciprofloxacin to
recover ciprofloxacin-resistant gram-negative bacilli. Resistant isolates were identified, and ciprofloxacin
MICs were determined. Resistant Escherichia coli isolates were also analyzed for urovirulence-associated loci.
Thirteen (2.9%) of 455 stools yielded ciprofloxacin-resistant E. coli (seven children), Stenotrophomonas malto-
philia (four children), and Achromobacter xylosoxidans and Enterobacter aerogenes (one child each). Neither the
subjects themselves nor members of their households used fluoroquinolones in the 4 weeks preceding collec-
tion. Six of the seven resistant E. coli isolates belonged to phylogenetic groups B2 and D, in which extrain-
testinal pathogenic E. coli bacteria are frequently found. All resistant E. coli isolates contained at least three
putative E. coli virulence loci. Most ciprofloxacin-resistant bacteria were resistant to additional antibiotics.
Potentially pathogenic bacteria that are resistant to therapeutically important antimicrobial agents are
excreted by some humans, despite these persons’ lack of exposure to the particular drugs. The sources of these
resistant organisms are unknown. This underrecognized reservoir of drug-resistant potential pathogens poses
public health challenges.
Acquired antimicrobial resistance in bacteria poses major
challenges for medical practice, public health, and the phar-
maceutical industry. Organisms with reduced susceptibilities
might proliferate and become more likely to disseminate when
selective pressure is exerted by antimicrobial agents, as has
been observed during prophylaxis of traveler’s diarrhea with
trimethoprim or trimethoprim-sulfamethoxazole (24). Human
populations that have not been exposed to antibiotics provide
opportunities to test the hypothesis that antibiotic-resistant
microflora can be acquired in the community in the absence of
selective pressure in a particular human host. If this hypothesis
is correct, efforts to determine the origins of such resistant
organisms may need to focus on determining the sources of
their nonselective acquisition by human hosts, such as foods or
other colonized humans.
Children are an easily defined population in which to deter-
mine if resistance to certain classes of antimicrobial agents can
occur in unexposed individuals. Fluoroquinolones (e.g., cipro-
floxacin), although extensively used in adults, are not approved
for routine childhood administration because of concern about
cartilage toxicity (10). Consequently, pediatric usage of fluo-
roquinolones, except for the treatment of selected illnesses,
such as cystic fibrosis, is quite unusual in North America.
Gram-negative bacilli, which are potential pathogens, are in-
trinsically susceptible to fluoroquinolones. Because children
are rarely exposed to fluoroquinolones, gram-negative bacilli
resistant to this class of antimicrobial agents in the fecal
microflora of children probably emerged via selective pres-
sure exerted in a different setting or host, before these
individuals ingested the organisms. To attempt to determine
if such resistant bacteria exist in the feces of children within
the general population who have no history of relevant
antimicrobial exposure, we conducted a prospective analysis
of stools from children who had not been directly exposed to
fluoroquinolones.
MATERIALS AND METHODS
Subjects and specimens. Between September 2001 and June 2002, stools were
provided anonymously by children without diarrhea who attended a general
ambulatory pediatric office in Seattle (Virginia Mason Sand Point Clinic). Sub-
jects were solicited by brochures provided to families during their visits. Families
completed questionnaires providing demographic information and details con-
* Corresponding author. Mailing address: Washington University
School of Medicine, Department of Pediatrics, Campus Box 8208, 660
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cerning any use of antimicrobial agents by the child during the 4 weeks preceding
collection of the stool specimen. The questionnaires also were used to record
antimicrobial usage by others in the household during this 4-week interval to
attempt to address the possibility that excretion of resistant flora could be related
to intrahousehold utilization of these drugs (11).
The stools were refrigerated at the pediatric office for up to 4 hours before
being processed. This study was approved by the Children’s Hospital and Re-
gional Medical Center (the sponsoring academic institution) and the Virginia
Mason Medical Center Institutional Review Boards.
Antibiotic resistance screening. To isolate ciprofloxacin-resistant gram-nega-
tive bacteria, stools were plated on MacConkey agar containing ciprofloxacin (1
mg per liter), prepared by adding antibiotic to autoclaved, cooling MacConkey
agar base (Becton-Dickinson, Sparks, Maryland). If there was growth on these
plates after overnight incubation at 35°C, a single resulting colony (“index cip-
rofloxacin-resistant bacteria”) was selected at random and its identity was deter-
mined by conventional tube biochemical assays, Vitek GNI (bioMe´rieux, Inc.,
Hazelwood, MO), API 20E (bioMe´rieux), and the Rapid NF Plus System
(Remel, Inc., Lenexa, KS). The identities of presumptive Stenotrophomonas
maltophilia and Achromobacter xylosoxidans isolates were confirmed by partial
16S rRNA gene sequencing (22). MICs to ciprofloxacin and moxifloxacin were
determined using the Etest (AB Biodisk, Solna, Sweden) (27) according to the
manufacturer’s recommendations. An isolate was considered resistant to cipro-
floxacin or moxifloxacin if its MIC for these agents was 4 mg per liter. Index
ciprofloxacin-resistant bacteria were stored in Luria-Bertani broth (26) with 15%
glycerol and ciprofloxacin (1 mg per liter) at 80°C.
To determine the proportion of total gram-negative bacteria excreted by the
subjects that were resistant to ciprofloxacin, all stool specimens were plated on
MacConkey agar containing no antibiotics. After overnight incubation at 35°C,
five lactose-fermenting colonies (as available) were selected at random (“coiso-
lated lactose-fermenting bacteria”) and frozen in Luria-Bertani broth with 15%
glycerol at 80°C until they were analyzed further. These coisolated lactose-
fermenting bacteria were subsequently tested for ciprofloxacin resistance if they
had been recovered from a patient whose stool yielded ciprofloxacin-resistant
Escherichia coli.
Index bacteria determined to be ciprofloxacin-resistant E. coli were O:H se-
rotyped at the Centers for Disease Control and Prevention by standard aggluti-
nation methods. The primer pairs 5ACGTACTAGGCAATGACTGG3-5AG
AACTCGCCGTCGATAGAAC3 and 5TGTATGCGATGTCTGAACTG3-
5CTCAATAGCAGCTCGGAATA3 were used to amplify gyrA and parC,
respectively, from boiled lysates of ciprofloxacin-resistant E. coli. These ampli-
cons, which include regions that can contain mutations associated with quinolone
resistance (7), were then sequenced bidirectionally.
Index resistant E. coli were tested for susceptibilities to ampicillin, ampicillin-
clavulinic acid, aztreonam, cefazolin, cefepime, ceftazidime, ceftriaxone, cefuro-
xime, ciprofloxacin, gentamicin, meropenem, piperacillin-tazobactam, and tri-
methoprim-sulfamethoxazole, using first the Vitek GNS-122 system (bioMe´rieux)
for screening and then a standard antimicrobial disk diffusion test for confirma-
tion. Susceptibilities of A. xylosoxidans to other antibiotic agents were tested by
the disk diffusion method only. The MICs of ciprofloxacin and moxifloxacin for
all quinolone-resistant organisms were determined by the Etest method (AB
Biodisk, Solna, Sweden). The antibiotic susceptibilities of S. maltophilia to a
battery of five other antibiotic agents (ceftazidime, chloramphenicol, doxycy-
cline, ticarcillin-clavulinic acid, and trimethoprim-sulfamethoxazole) were also
determined by the Etest method. The results generated from both the disk
diffusion tests and the MIC Etests were interpreted using the criteria suggested
by the Clinical and Laboratory Standards Institute (3, 4).
Index ciprofloxacin-resistant E. coli isolates were assigned to one of four
main phylogenetic groups (A, B1, B2, or D) (12) by multiplex PCR (2). They
were also tested for 47 virulence genes, including 34 virulence-associated
genes of extraintestinal pathogenic E. coli and 13 papA (structural-subunit)
alleles, using established PCR-based assays (15, 16). Appropriate positive and
negative controls were included. An aggregate virulence score was calculated
for each isolate as the number of virulence genes detected. E. coli isolates
were additionally classified as extraintestinal and pathogenic if they contained
at least two of the following five genes: papA or papC, sfa/foc, afa/dra, iutA,
and kpsMII (14). Index and coisolated ciprofloxacin-resistant E. coli isolates
were tested for clonal relatedness by pulsed-field gel electrophoresis, follow-
ing XbaI digestion (1).
The statistical significances of differences between proportions were deter-
mined using the two-tailed Fisher’s exact test.
RESULTS
Stools from 455 children without diarrhea were studied. The
median age was 3.4 years, and the range was 18 days to 19
years, 8 months. Only two subjects were older than 18 years,
the age below which the U.S. Food and Drug Administration
does not recommend the use of fluoroquinolones. Of these, 14
(3.1%) yielded gram-negative bacteria on ciprofloxacin-sup-
plemented MacConkey agar. Of these 14 bacteria, 13 organ-
isms, consisting of E. coli (seven children) representing five
different serogroups, S. maltophilia (four children), and E.
aerogenes and A. xylosoxidans (one child each), had MICs of
ciprofloxacin and moxifloxacin ranging from 4 to 32 mg per
liter, with the E. coli isolates demonstrating the highest degrees
of resistance (Table 1). All seven resistant E. coli isolates
contained Ser83Leu and Asn87Asp mutations in gyrA and a
Ser83Ile mutation in parC; two also contained a Glu84Val
mutation in parC. The resistant E. aerogenes isolate had a
Ser83Ile mutation in gyrA.
Six of the seven ciprofloxacin-resistant E. coli isolates were
derived from phylogenetic groups B2 and D (three isolates
each), which are epidemiologically associated with extraintes-
tinal virulence (14). The virulence-associated traits of extrain-
testinal pathogenic E. coli found in the seven isolates, in de-
scending order of prevalence, consisted of malX/pathogenicity
island marker and fyuA/yersiniabactin system (six isolates
each); fimH/type 1 fimbriae and iutA/aerobactin system (five
isolates each); traT/serum resistance associated (four isolates),
iha/putative adhesin/siderophore, and kpsMII/group II capsule
(three isolates each); ompT/outer membrane protease (two
isolates); and papEF/P fimbria minor subunits, K1/kpsM vari-
ant, and ibeA/invasion of brain endothelium A (one isolate
each). The median aggregate virulence score was 7 (range, 3 to
8). Three ciprofloxacin-resistant isolates contained both iutA
and kpsMII and one contained both papEF and kpsMII and
were classified as extraintestinal pathogenic E. coli (14).
On plain MacConkey agar plates, stools from six of the
seven children with ciprofloxacin-resistant E. coli yielded at
least one additional lactose-fermenting colony that also proved
to be a ciprofloxacin-resistant E. coli isolate. All such coiso-
lated ciprofloxacin-resistant E. coli isolates were indistinguish-
able from the corresponding index resistant isolates, according
to XbaI pulsed-field gel electrophoresis patterns.
The spectrum of antimicrobial resistance in the 13 resistant
organisms was not limited to fluoroquinolones. Five of the
seven index E. coli isolates were fully resistant to tri-
methoprim-sulfamethoxazole; three were also resistant to nar-
row- and broad-spectrum cephalosporins. None of the 13 chil-
dren whose stool specimens yielded ciprofloxacin-resistant
gram-negative bacilli either used a fluoroquinolone or resided
in a household where a fluoroquinolone was used during the 4
weeks before specimen collection, based on recall. We de-
tected no influence of other antibiotics on the detection of a
quinolone-resistant organism. Fifty-three (11.6%) of the 455
children used antibiotics during the 4 weeks before stool col-
lection, including 2 (15.4%) of the 13 children with ciprofloxa-
cin-resistant gram-negative bacilli in their stools (P  0.65).
Eighty-nine (19.6%) of the children lived in households where
at least one other household member used antibiotics during
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this interval, including 3 (23.1%) of the 13 children excreting
ciprofloxacin-resistant gram-negative bacilli (P  0.72).
DISCUSSION
In this prospective study, we found ciprofloxacin-resistant
gram-negative bacteria in the stools of children, even though
the children and the other members of their households had
not used these antimicrobial agents in the 4 weeks before
culture. Thus, our data demonstrate that resistant bacteria
belonging to species that are normally intrinsically susceptible
to fluoroquinolones can be found in, and probably have colo-
nized, the intestinal tracts of individuals who had not been
exposed to fluoroquinolones. This finding suggests that hu-
mans can acquire bacteria resistant to clinically useful antimi-
crobial agents without having experienced selective antimicro-
bial pressure for those agents either directly or indirectly via a
household member.
Even though gram-negative bacilli are members of the com-
mensal gastrointestinal microflora, these organisms can cause
serious extraintestinal infections in both healthy and immuno-
compromised hosts (20). Fluoroquinolones are often used to
treat extraintestinal infections with gram-negative bacteria.
Though our study focused on children, the findings of cipro-
floxacin-resistant gram-negative bacilli in antibiotic-naı¨ve chil-
dren seems likely to also be relevant to adults who have not
been exposed to these antimicrobial agents.
The pathogenic potentials of the resistant organisms identi-
fied in this study are uncertain, but it is of concern that most of
the ciprofloxacin-resistant E. coli isolates had characteristics
that implicate them as uropathogens. Thus, these resistant
organisms should not be dismissed as merely harmless mem-
bers of the commensal microflora. It is also noteworthy that
the resistant E. coli isolates, when present, were usually quan-
titatively predominant within the facultative coliform micro-
flora, rather than a minority clone, as demonstrated by their
presence among five arbitrarily picked colonies of gram-nega-
tive fecal bacteria that grew on nonselective media. The ap-
parent urovirulence potentials of these E. coli isolates contrast
with previous surveys, in which ciprofloxacin-resistant E. coli
isolates from humans contained few such pathogenicity-asso-
ciated loci (14, 16, 17).
Our finding of ciprofloxacin-resistant gram-negative lactose-
fermenting bacteria other than E. coli also has potential clin-
ical implications. For example, because fluoroquinolones are
used to treat S. maltophilia infections (5, 9), fluoroquinolone
resistance in this species could lead to therapeutic failures if
the resistant organisms were to cause infection.
It is not possible from our data to determine the source of
acquisition of these resistant enteric bacteria. However, it is
plausible that the source was food (28, 29, 31). In the United
States, fluoroquinolones (e.g., enrofloxacin) have been used in
cattle since 1998 and in chickens and turkeys from 1995 to































E. coli O26:H4 3 5.3 M 32 B2 iha, fimA, fyuA,
iutA, kpsMII,
ompT, malX









E. coli related to O2,
O50:H34
4 1.6 M Azithromycind,
minocyclinee
4 D fimA, iutA, ibeA AM, AMC, CZ, GM,
SXT
E. coli O untypeable:NM 0 9.3 F Clindamycine 32 A fimA, fyuA, iutA AM, SXT
E. coli O102:H6 2 4.8 M 32 D fimA, iutA, malX AM, CZ, GM, SXT
E. aerogenes 0.5 F 4f AM, AMC, CAZ,
CRO, CXM, CZ
A. xylosoxidans 0.2 F 6 ATM, CRO
S. maltophilia 0.6 M Cephalexine 4 CL
S. maltophilia 0.8 F 4 CAZ
S. maltophilia 1.3 M 6 CAZ, CL
S. maltophilia 1 F Amoxicillind 8 CL
a Characteristics of isolates that were resistant to fluoroquinolones, and of the subjects from whom they were recovered. For fluoroquinolone-resistant E. coli,
additional data are reported, including O:H serotypes, frequency of coisolated resistant E. coli, and virulence genotypes. The virulence loci not detected in any of the
ciprofloxacin-resistant E. coli were papA, papC, papG, sfa/focDE, sfaS, focG, afa/draBC, bmaE, gafD, hlyD, cnf1, cdtB, K2 kpsM variant, kpsMTIII, rfc, cvaC, iss, and
H7 fliC.
b M, male; F, female.
c AM, ampicillin; AMC, ampicillin-sulbactam; ATM, aztreonam; CAZ, ceftazidime; CRO, ceftriaxone; CXM, cefuroxime; CZ, cefazolin; CL, choramphenicol; GM,
gentamicin; SXT, trimethoprim-sulfamethoxazole.
d Taken by subject.
e Taken by another person in subject’s household.
f Rounded up from an intermediate value of 3 in the Etest.
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2005. Their use provides a selective advantage to bacteria that
are resistant to these agents and potentially contributes to
dissemination of these resistant bacteria to humans through
the food supply. Bacteria resistant to enrofloxacin are typically
resistant to ciprofloxacin. It is therefore conceivable that the
resistance in these human source strains was derived from the
use of these antimicrobial agents in food animals. Provoca-
tively, in Australia, where fluoroquinolones are banned in food
animals, domestically acquired fluoroquinolone-resistant
Campylobacter infections are quite rare (30). It is also possible
that sources for the resistant bacteria isolated in this study
could have been family members who received a fluoroquin-
olone more than 4 weeks before the children’s stool samples
were submitted (because it is not known how long such organ-
isms persist in human fecal microflora) or people in the com-
munity outside the subjects’ households. Indeed, daycare stud-
ies have demonstrated nonfamilial transmission of E. coli
isolates resistant to trimethoprim (8, 25). Some of the children
in our study who were 1 year of age and whose stools con-
tained resistant organisms might have consumed exclusively
breast milk or infant formula and not been exposed directly to
food-borne bacteria.
The possibility that the use of antimicrobial agents in food
animals has contributed to the selection of antibiotic-resistant
bacteria and their dissemination to humans through the food
supply is a concern raised by several previous studies. For
example, human infections with fluoroquinolone-resistant
Campylobacter jejuni have been attributed to the use of fluo-
roquinolones in poultry production (6, 14). Additionally, the
recent widespread emergence of multidrug-resistant uropatho-
genic E. coli and the rising incidence of fluoroquinolone-resis-
tant urinary E. coli (19, 23) demonstrate the risk fluoroquin-
olone-resistant gram-negative bacilli pose to the general
population (13, 14, 16, 18).
We note that our study has several limitations. First, recall
biases could have influenced, either positively or negatively,
reports of recent antibiotic use in the households. Second, we
were selective in the quantity of data we were able to accrue,
and we propose that future studies address potentially relevant
factors, such as dietary questions, household size, daycare at-
tendance, and breast milk consumption. Third, the 1-month
period for exposure assessment, while seemingly reasonable
for this exploratory study, might have been too limited. A
recent study demonstrated long-term carriage of tetracycline-
resistant E. coli in stools of infants (21), which raises the pos-
sibility of selective events occurring at times well before sam-
pling. Fourth, we were unable to confirm compliance with our
request that stools be submitted once from each subject. Fifth,
we were unable to monitor how many stools were submitted
from children within the same household, though our large
sample size mitigates biases introduced by intrafamily repeat
submissions. Sixth, in this open U.S. population, in a study in
which specimens were submitted anonymously, we were unable
to use pharmacy databases to confirm medication use or non-
use. Despite these limitations, we have demonstrated that chil-
dren who were highly unlikely to have been exposed to fluo-
roquinolones shed in their stools bacteria that had acquired
resistance to these antibiotics. Acquisition of an antimicrobial-
resistant gastrointestinal microflora by persons in the commu-
nity who had not been exposed to antimicrobial agents poses
considerable challenges. Further research should determine
the prevalence, and spectrum, of antibiotic resistance in human
reservoirs in the community. Such investigations ideally should
also address the age-specific duration and intensity of shedding
of the resistant organisms, mechanisms of development of re-
sistance in these organisms, and molecular comparisons of
antimicrobial-resistant human, food, and animal isolates to
clarify the sources of the resistant isolates encountered in hu-
mans. These data will be helpful in confirming or refuting the
potential association between the use of antimicrobial agents
in food animals and intestinal carriage of antibiotic-resistant
fecal organisms by non-antibiotic-exposed humans.
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